An Open-Label Study of the Safety and Efficacy of Atiprimod Treatment for Patients With Refractory or Relapsed Multiple Myeloma

Inclusion Criteria:

- documented history of multiple myeloma,

- failed at least two prior regimens for multiple myeloma,

- 18 years of age or older,

- ECOG(Zubrod)PS of 0 to 2,

- screening evaluation for determining eligibility prior to enrollment,

- signed informed consent form,

Exclusion Criteria:

- concomitant therapy medications including corticosteroids or other chemotherapy that
is or may be active against myeloma ,

- renal insufficiency (serum creatinine levels of > 2mg/dL),

- mucosal bleeding,

- any condition which in the opinion of the Investigator, places the patient at
unacceptable risk if he/she were to participate in the study.

- clinically relevant active infection or co-morbid medical conditions.

- prior malignancy(within the last 3 years) except for adequately treated basal cell or
squamous cell skin cancer, in situ cervical cancer, or other cancer for which the
patient is has been disease-free for at least 3 years.

- patients with non-secretory myeloma.

- as atiprimod is a potent inhibitor or CYP2D6, patients taking drugs that are
substrates of CYP2D6(e.g. beta blockers, antidepressants and antipsychotics) will be
excluded.